Flynn Pharma
James Leighton-Scott is an accomplished Chief Medical Officer at Flynn Pharma since May 2021, overseeing medical affairs, pharmacovigilance, and medical information. Previously, James held a significant role as Senior Vice President Medical at Mundipharma Research Limited from July 2009 to October 2020, where responsibilities included managing global clinical development and drug safety. In addition to various executive roles at Mundipharma, James directed the consolidation of R&D operations and led regulatory affairs on an interim basis. Earlier experience includes positions as Senior Medical Advisor at Napp Pharmaceuticals Limited and Clinical Research Physician at LCG Bioscience Limited, alongside foundational training as a House Officer at Barts Health NHS Trust. James holds both a Bachelor of Medicine, Bachelor of Surgery (MBBS) and a Bachelor of Science (BSc Hons) in Physiology and Basic Medical Sciences from St Bartholomew's and The Royal London School of Medicine and Dentistry.
This person is not in any teams
Flynn Pharma
Flynn Pharma is a privately held pharmaceutical company focused on primary care, secondary care and speciality medicine. We are engaged in a wide range of therapy areas including psychiatry, paediatrics, gastroenterology, anti-infective medicine, women’s health, and emergency medicine. We introduce new products, improve existing formulations or add new indications to benefit patients. In everything we do, we endeavour to place patients at the centre of our thinking and efforts.